For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
|Videos|November 13, 2014
The Evolving Role of Chemotherapy for Hormone-Sensitive Prostate Cancer
Author(s)Christopher Sweeney, MBBS
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.
Advertisement
Clinical Pearls
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.
- Oncologists have been trained in the use of chemotherapy — they are aware of the side effects.
- The side effect profile of chemotherapy is essentially the same as when used for castration-resistant disease.
- The question remains: Is there a difference in using docetaxel in the hormone-sensitive or castration-resistant settings?
- The rate of neutropenic fever was slightly higher in the CHAARTED study (8%) compared with the TAX 327 study (3%).
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5